Friday, October 31, 2014

Neurocrine Biosciences Receives Breakthrough Therapy Designation …

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. More …